Furthermore, it is possible that longer follow‐up would reveal that TTC delays has a more pronounced survival impact in patients with hormone receptor‐positive BC where recurrence risk tends follow a longer course compared to HER2‐positive BC and TNBC.32 Here, ERBB2 is linked to breast cancer.